KR102819051B1 - Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 - Google Patents

Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 Download PDF

Info

Publication number
KR102819051B1
KR102819051B1 KR1020187028377A KR20187028377A KR102819051B1 KR 102819051 B1 KR102819051 B1 KR 102819051B1 KR 1020187028377 A KR1020187028377 A KR 1020187028377A KR 20187028377 A KR20187028377 A KR 20187028377A KR 102819051 B1 KR102819051 B1 KR 102819051B1
Authority
KR
South Korea
Prior art keywords
ser
val
leu
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028377A
Other languages
English (en)
Korean (ko)
Other versions
KR20180118746A (ko
Inventor
니꼴라 뿌와리에
꺄롤린 마리
Original Assignee
오제 이뮈노테라프틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오제 이뮈노테라프틱스 filed Critical 오제 이뮈노테라프틱스
Publication of KR20180118746A publication Critical patent/KR20180118746A/ko
Application granted granted Critical
Publication of KR102819051B1 publication Critical patent/KR102819051B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187028377A 2016-02-29 2017-02-28 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 Active KR102819051B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
US62/301,271 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
KR20180118746A KR20180118746A (ko) 2018-10-31
KR102819051B1 true KR102819051B1 (ko) 2025-06-12

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028377A Active KR102819051B1 (ko) 2016-02-29 2017-02-28 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도

Country Status (22)

Country Link
US (1) US11230602B2 (https=)
EP (1) EP3423496B1 (https=)
JP (1) JP7053479B2 (https=)
KR (1) KR102819051B1 (https=)
CN (1) CN109195987B (https=)
AU (1) AU2017225495B2 (https=)
CY (1) CY1122072T1 (https=)
DK (1) DK3423496T3 (https=)
ES (1) ES2737307T3 (https=)
HR (1) HRP20191445T1 (https=)
HU (1) HUE045183T2 (https=)
IL (1) IL261330B2 (https=)
LT (1) LT3423496T (https=)
MA (1) MA43767B1 (https=)
MD (1) MD3423496T2 (https=)
ME (1) ME03446B (https=)
PL (1) PL3423496T3 (https=)
PT (1) PT3423496T (https=)
RS (1) RS59223B1 (https=)
SI (1) SI3423496T1 (https=)
SM (1) SMT201900460T1 (https=)
WO (1) WO2017149394A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
AU2019265888B2 (en) * 2018-05-10 2026-04-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US20220273713A1 (en) * 2019-06-28 2022-09-01 The University Of Melbourne Method of inhibiting or activating gamma delta t cells
EP4065605A4 (en) 2019-11-26 2023-07-12 Ramot at Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
WO2021222227A1 (en) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd127 and use thereof
AU2021275055A1 (en) * 2020-05-18 2023-02-02 Mouhannad Jumaa Composition for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056984A1 (en) 2011-10-19 2013-04-25 Effimune Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
PE20170687A1 (es) * 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056984A1 (en) 2011-10-19 2013-04-25 Effimune Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates

Also Published As

Publication number Publication date
MA43767B1 (fr) 2019-08-30
PL3423496T3 (pl) 2020-01-31
IL261330A (en) 2018-10-31
LT3423496T (lt) 2019-09-25
HUE045183T2 (hu) 2019-12-30
EP3423496B1 (en) 2019-07-03
JP2019515648A (ja) 2019-06-13
SI3423496T1 (sl) 2019-10-30
AU2017225495B2 (en) 2024-05-09
IL261330B (en) 2022-11-01
SMT201900460T1 (it) 2019-09-09
PT3423496T (pt) 2019-09-05
AU2017225495A1 (en) 2018-08-23
CN109195987B (zh) 2022-05-27
JP7053479B2 (ja) 2022-04-12
RS59223B1 (sr) 2019-10-31
BR112018067479A2 (pt) 2019-01-15
US11230602B2 (en) 2022-01-25
KR20180118746A (ko) 2018-10-31
MA43767A (fr) 2019-01-09
MD3423496T2 (ro) 2020-01-31
HRP20191445T1 (hr) 2019-11-15
US20200308288A1 (en) 2020-10-01
DK3423496T3 (da) 2019-08-19
CN109195987A (zh) 2019-01-11
ME03446B (me) 2020-01-20
CY1122072T1 (el) 2020-11-25
CA3014313A1 (en) 2017-09-08
EP3423496A1 (en) 2019-01-09
IL261330B2 (en) 2023-03-01
ES2737307T3 (es) 2020-01-13
WO2017149394A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
KR102819051B1 (ko) Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도
CN112175081B (zh) 抗cd137分子及其用途
KR102692379B1 (ko) Pd-1과 특이적으로 결합하는 항체 및 사용 방법
CN111788225B (zh) 抗cd38抗体及与抗cd3和抗cd28抗体的组合
KR102569813B1 (ko) Cd73에 대항한 항체 및 그의 용도
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR20230038311A (ko) 항-cd73 항체와의 조합 요법
KR102724790B1 (ko) 항 cd147 항체
CN113372434A (zh) 包含tnf家族配体三聚体的抗原结合分子
CN107074953A (zh) 人源化抗ox40抗体及其用途
KR102901666B1 (ko) 항-인간 cd19 항체
KR20180089510A (ko) CD32b를 표적화하는 항체 및 그의 사용 방법
AU2020316495A1 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
KR102920217B1 (ko) 인간화 항-vegf 단클론 항체
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
KR20240007760A (ko) 항-icos 항체의 용도
CN101516913A (zh) Adcc活性得到增强的抗体及其制造方法
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181001

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220225

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240416

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250402

PG1601 Publication of registration